{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-066456","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.363292+00:00","generated_at":"2026-06-11T11:03:34.767560+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Intensity Therapeutics reports Q2 2023 results; IPO nets $20.5M, INT230-6 shows survival benefit in sarcoma","bullets":["Closed upsized IPO of 3.9M shares at $5.00/sh, net proceeds $20.5M; cash runway extended into early Q3 2025.","INT230-6 data at ASCO: median OS 21.3 months in refractory metastatic sarcoma vs historical 7-10 months.","Net operating loss $1.2M in Q2 2023 vs $1.9M in Q2 2022; non-operating loss $2.3M from convertible debt discount included.","Plan to file IND for phase 3 study of INT230-6 in soft tissue sarcoma by end of 2023.","Additional INVINCIBLE breast cancer data expected by year-end; phase 2/3 program planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-066456","json":"https://secwatch.observer/filing/0001213900-23-066456.json","markdown":"https://secwatch.observer/filing/0001213900-23-066456.md","text":"https://secwatch.observer/filing/0001213900-23-066456.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000121390023066456/0001213900-23-066456-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000121390023066456/ea183398-8k_intensity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:03:34.767560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0580e5a9f586e1ad3c3a801137c8f8d0288889a1","claim":"INTENSITY THERAPEUTICS, INC. reported second quarter ended June 30, 2023 results: net income Net Operating Loss for the second quarter ended June 30, 2023 was $1.2 million.","evidence_excerpt":"Intensity Therapeutics, Inc. (the “ Company ”) released its financial results for the quarter ended June 30, 2023. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567264/000121390023066456/0001213900-23-066456-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"Net Operating Loss for the second quarter ended June 30, 2023 was $1.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}